FAQ / Contact us

This page is under construction – only for demonstration purposes.

Contact

You can contact us trough lectoraat.ag@hsleiden.nl

Newsletter

Please enter your details, and you will receive an email when there is new information added to you area(s) of interest.

Partners

  • E. Baars, Louis Bolk Institute/ University of Applied Sciences Leiden, The Netherlands
  • M. Emeje, National Institute for Pharmaceutical Research & Development, Nigeria
  • M. Fernandez, Portales IAVH, Spain
  • M. Frass, Austrian Umbrella Organisation for Medical Holistic Therapy/ WissHOM, Austria
  • M. Guldas, Uludag University, Turkey
  • X. Hu, Univ. of Southampton, School of Primary Care, Population Sciences and Medical Education, UK
  • R. Huber, University Medical Centre Freiburg, Germany
  • M. Johnson, Organic Research Centre, UK
  • E. Katuura, Makerere University, Uganda
  • P. Little, Univ. of Southampton, School of Primary Care, Population Sciences and Medical Education, UK
  • J. Liu, Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, China
  • D. Martin, University of Witten-Herdecke, Germany
  • M. Moore, Univ. of Southampton, School of Primary Care, Population Sciences and Medical Education, UK
  • T. Nicolai, Eurocam, Belgium
  • E. Oppong Bekoe, University of Ghana, School of Pharmacy, Ghana
  • P. Panhofer, Private Medical University, Sigmund Freud University, Austria
  • B. Prakash, The University of Trans-Disciplinary Health Sciences & Technology, India
  • R. Sanogo, University of Sciences, Techniques and Bamako Technologies (USTTB), Faculty of Pharmacy, Mali
  • K. Sørheim, Norwegian Centre for Organic Agriculture, Norway
  • H. Szőke, University of Pécs, Hungary
  • E. van der Werf, HRI, UK
  • D. Vankova, Medical University of Varna, Bulgaria
  • N. van Steenbergen, University of Applied Sciences Leiden, The Netherlands
  • L. Veldman, University of Applied Sciences Leiden, The Netherlands
  • H. van Wietmarschen, Louis Bolk Institute, The Netherlands
  • P. Weiermayer, OEGVH/ WissHom, Austria
  • M. Willcox, University of Southampton, UK
  • L. Windsley, Organic research centre, UK
  • F. Yutong, Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, China

FAQ

What is the GIFTS-AMR global research agenda?

The GIFTS-AMR global research agenda describes a global research agenda on Traditional, Complementary & Integrative Healthcare (TCIH) strategies & natural medicinal products to prevent and treat infections and reduce antimicrobial resistance, primarily focusing on health/resilience promotion. In addition, the connection of this agenda to two global AMR research agendas and suggested advocacy actions are described. Four GIFTS-AMR research themes linked to 14 research priorities, prioritized research projects for the next 10 years and contributions to two global AMR research agendas are presented in a table. See Education > GIFTS-AMR global research agenda 

What are whole medical systems?

Whole medical systems (WMSs) are complete systems of theory and practice that have evolved independently over time in different cultures and apart from conventional medicine or Western medicine. Over time, several types of WMSs have been developed in many non-Western cultures but also in Western cultures (Baars and Hamre, 2017).

What is TCIH?

Traditional, complementary and integrative healthcare (TCIH) refers to the respectful collaboration between various systems of healthcare and their health professionals with the aim of offering a person-centred and holistic approach to health (The People’s Declaration for Traditional, Complementary and Integrative Healthcare​).

What is the One Health research agenda on AMR?

The One Health Priority Research Agenda on Antimicrobial Resistance (AMR) sets out for the first time the priorities for which the Food and Agriculture Organization of the United Nations, the UN environment programme, the WHO and the World Organization for Animal Health – as leaders in the multilateral system on human, animal, plant, and environmental health – will advocate to promote research and investment in the response to AMR. The Research Agenda results from extensive stakeholder and expert engagement and was developed using a sound scientific methodology. The process identified major gaps in knowledge and evidence that require urgent scientific attention and resources (A one health priority research agenda for antimicrobial resistance).

What is the WHO research agenda on AMR?

The global research agenda for antimicrobial resistance in human health prioritizes 40 research topics for evidence generation to inform policy by 2030. It aims to guide policy-makers, researchers, funders, implementing partners, industry and civil society in generating new evidence to inform antimicrobial resistance policies and interventions as part of efforts to address antimicrobial resistance, especially in low-and-middle-income countries.

The research agenda is global in scope and focuses on antimicrobial resistance in the human health sector, especially infections caused by the WHO bacterial priority pathogens and WHO fungal priority pathogens with critical importance for antimicrobial resistance (such as Candida auris, Aspergillus fumigatus and Cryptococcus neoformans), and drug-resistant Mycobacterium tuberculosis (Global research agenda for antimicrobial resistance in human health).